HANTAVIRUS vaccine development remains limited despite a deadly Andes virus outbreak linked to cruise ship infections.
Hantavirus Vaccine Gap Complicates Outbreak Preparedness
A deadly hantavirus outbreak linked to the MV Hondius cruise ship has renewed attention on the limited clinical tools available to prevent or treat this rare but severe zoonotic infection. Three people who had been onboard tested positive for hantavirus, including one passenger who died. A further five suspected infections have been reported, with two additional deaths.
The outbreak has been attributed to Andes virus, a hantavirus species that can occasionally spread between people in close contact. Scientists suspect some travelers might have been infected in Argentina before boarding the ship. Unlike many hantavirus species, which typically spread through aerosolized particles from rodent urine, droppings, or saliva, Andes virus has documented potential for person-to-person transmission.
There are currently no specific treatments or vaccines for Andes virus infection. Although hantavirus infections remain rare, some species have reported fatality rates of up to 50%, making prevention, early recognition, and outbreak preparedness clinically important.
Why Andes Virus Vaccines Remain Elusive
For more than three decades, vaccine researchers have pursued protection against hantavirus species capable of causing human disease, including Andes virus. Military interest has been strong because rodent borne viruses can pose risks to troops operating in affected environments.
A key advance has been the development of hamster models that reproduce a lethal disease similar to human hantavirus pulmonary syndrome. These models allow researchers to test vaccines and therapeutics in a setting that more closely reflects severe human disease.
Phase I clinical trials have evaluated vaccines for Andes virus, Hantaan virus, and Puumala virus. The Andes DNA vaccine induced neutralizing antibodies in humans, a promising marker because neutralizing antibodies are considered important for protection. However, the vaccine requires at least three doses, making implementation more complex than a single dose or simple prime boost strategy.
The rarity and geographic dispersion of Andes virus cases also make a conventional Phase III efficacy trial difficult. As a result, researchers are exploring creative licensing approaches, including use of neutralizing antibodies as a correlate of protection. Funding for advanced development remains another major barrier.
Clinical Implications for Future Hantavirus Outbreaks
For physicians, the outbreak reinforces the importance of considering hantavirus in compatible clinical and exposure contexts, particularly after travel to areas where reservoir rodents are present. Climate related shifts in rodent populations and human movement into rodent habitats could influence future case patterns, although spillover events remain inherently unpredictable.
Until a licensed hantavirus vaccine or targeted therapy becomes available, clinical readiness will depend on rapid recognition, supportive care, infection control awareness for Andes virus, and public health surveillance.
Reference
Basu M. There is no vaccine for deadly hantavirus: what that means for future outbreaks. Nature. 2026;DOI: 10.1038/d41586-026-01494-9.
Featured Image: xxx on Adobe Stock.
